Breaking News Instant updates and real-time market news.

MGEN

Miragen Therapeutics

$0.69 /

+0.0554 (+8.73%)

16:24
12/11/19
12/11
16:24
12/11/19
16:24

Miragen Therapeutics to cut Phase 2 SOLAR enrollment, focus pipeline on MRG-229

Miragen Therapeutics announced a series of strategic changes across its business that are intended to reallocate its existing capital to deliver milestones in 2020. These changes include a revised development strategy aimed at delivering data in 2020 from a modified Phase 2 SOLAR clinical trial of cobomarsen in cutaneous T-cell lymphoma, or CTCL, consulting with the FDA to define a development path for cobomarsen in adult T-cell leukemia/lymphoma, or ATLL, and focusing future pipeline development efforts primarily on MRG-229, a novel second generation miR-29 mimic and potential treatment in patients with idiopathic pulmonary fibrosis (IPF). Together with its updated development strategy, the company is streamlining operations and reallocating its existing resources, which includes a workforce reduction that will impact approximately 18 employees. After changes to the SOLAR clinical trial and the reduction in workforce, the company believes its cash and cash equivalents will now be sufficient to fund its operations into Q4 of 2020. The company announced that it will stop the enrollment of new patients in its Phase 2 clinical trial of cobomarsen, SOLAR, effective as of the end of the year. Patients enrolled in the trial at that time will continue to be evaluated for safety and clinical response. The company initially planned to enroll up to 126 patients and now expects to enroll approximately 30 patients. Despite the reduction in patient enrollment, the company believes that evaluation of data from this set of patients can provide important evidence regarding the safety and efficacy of cobomarsen for the treatment of CTCL in a shorter period of time and require fewer resources. The company also believes that obtaining controlled clinical data from this cohort of patients may allow for a better assessment of the clinical potential of cobomarsen as compared to data from its Phase 1 trial. The company intends for this controlled clinical data to form the basis of determining what additional clinical investigation of cobomarsen in CTCL is warranted, if any, and what would be required to potentially obtain regulatory approval. Topline data from this amended trial is expected to be announced in Q3 of 2020. In addition to CTCL, Miragen is also evaluating cobomarsen in a Phase 1 basket trial of other cancers where the disease process appears to be correlated with an increase in miR-155 levels, ATLL, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. In this clinical trial, the company believes that cobomarsen has demonstrated promising interim results in several ATLL patients. Based on these interim results, the company is announcing that it is focusing its cobomarsen expansion indication efforts on ATLL and will request a meeting with the FDA to explore a potential expedited development pathway for cobomarsen in ATLL. The company expects to have a meeting with the FDA in Q2. The company is developing miR-29 mimics or replacements for miR-29, a microRNA that is found at abnormally low levels in a number of pathological fibrotic conditions. The company's lead microRNA-29 mimics are remlarsen and MRG-229. Remlarsen is the company's most advanced product candidate in fibrosis, which is currently being evaluated in a Phase 2 clinical trial assessing its safety, tolerability, and activity in the potential prevention or reduction of keloid formation in patients with a history of keloid scars, a form of pathological scarring. The company reported interim data from this clinical trial, which suggests that remlarsen was generally safe and well tolerated, treatment had no negative effect on healing reported and initial volume reductions in treated keloids compared to placebo in a subset of patients were observed. Based on this data, the company has decided to continue its analysis of patient data at the one-year primary endpoint of the clinical trial. With this data, the company may seek a collaboration partner for the future development of remlarsen. In addition, based on preclinical data with MRG-229, the company announced that its pipeline development efforts and allocation of future capital will be primarily focused on the development of MRG-229 for IPF. The company believes that the efficacy and safety profile of MRG-229 positions it as a potentially differentiated approach to the treatment of IPF. Miragen expects to report additional preclinical-safety and -efficacy data during the first half of 2020. This program is supported by a grant in collaboration with the National Institutes of Health and Yale University.

MGEN Miragen Therapeutics
$0.69 /

+0.0554 (+8.73%)

08/19/19 H.C. Wainwright
Miragen Therapeutics initiated with a Buy at H.C. Wainwright
03/21/19 Oppenheimer
Miragen Therapeutics assumed with an Outperform at Oppenheimer
01/04/19 Baird
Miragen Therapeutics initiated with an Outperform at Baird
12/31/18 B. Riley Securities
Miragen Therapeutics resumed with a Buy at B. Riley FBR

TODAY'S FREE FLY STORIES

Technical Analysis
NASDAQ market internals summary » 16:17
11/27/20
11/27
16:17
11/27/20
16:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Volume is above average for this time of day. Breadth is bullish across the board. Advancing Issues: 2249 / Declining Issues: 1300 -- for a ratio of 1.7 to 1. Advancing Volume: 2,673,092,000 / Declining Volume: 682,470,000 -- for a ratio of 3.9 to 1. New 52-Week Highs: 302 / New 52-Week Lows: 14.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 16:16
11/27/20
11/27
16:16
11/27/20
16:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

General news
Week of 11/16 Money Supply to be released at 16:30  16:15
11/27/20
11/27
16:15
11/27/20
16:15
 
General news
Week of 11/25 Fed Balance Sheet to be released at 16:30  16:15
11/27/20
11/27
16:15
11/27/20
16:15
 
General news
Week of 11/25 Fed Balance Sheet to be released at 16:30  16:15
11/27/20
11/27
16:15
11/27/20
16:15
 
General news
Week of 11/16 Money Supply to be released at 16:30  16:15
11/27/20
11/27
16:15
11/27/20
16:15
 
Hot Stocks
NFL postpones Ravens-Steelers game from Sunday to Tuesday » 15:32
11/27/20
11/27
15:32
11/27/20
15:32
BYD

Boyd Gaming

$39.57 /

+0.18 (+0.46%)

, MGM

MGM Resorts

$28.64 /

+0.24 (+0.85%)

, CZR

Caesars

$70.04 /

+0.73 (+1.05%)

, CHDN

Churchill Downs

$185.21 /

+0.4 (+0.22%)

, PENN

Penn National

$73.31 /

+0.91 (+1.26%)

, WYNN

Wynn Resorts

$101.26 /

+0.86 (+0.86%)

, LVS

Las Vegas Sands

$56.61 /

+0.09 (+0.16%)

, GAN

Gan Limited

$16.47 /

+0.3 (+1.86%)

, PDYPY

Flutter Entertainment

$0.00 /

+ (+0.00%)

, WIMHY

William Hill

$0.00 /

+ (+0.00%)

, DKNG

DraftKings

$52.59 /

+2.35 (+4.68%)

The National Football…

The National Football League said in a statement: "The Baltimore Ravens-Pittsburgh Steelers game has been rescheduled again, this time from Sunday to Tuesday at 8 p.m. ET on NBC. Originally scheduled to be played on Thursday night, the game is being moved for a second time, once again due to COVID-19 concerns stemming from an outbreak within the Ravens organization. With the move to Tuesday, the Ravens' Week 13 game originally scheduled for Thursday against the Dallas Cowboys will be moved to a Monday doubleheader on Dec. 7." Publicly traded companies in the space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

ShowHide Related Items >><<
WIMHY William Hill
$0.00 /

+ (+0.00%)

MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DKNG DraftKings
$52.59 /

+2.35 (+4.68%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

CHDN Churchill Downs
$185.21 /

+0.4 (+0.22%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

10/30/20 Argus
Boyd Gaming upgraded to Buy from Hold at Argus
10/30/20 Argus
Boyd Gaming upgraded to Buy from Hold at Argus
10/28/20 Union Gaming
Union Gaming says 'better late than never,' upgrades Red Rock Resorts to Buy
10/27/20 Stifel
Boyd Gaming price target raised to $48 from $28 at Stifel
MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

11/10/20 Wells Fargo
IAC price target raised to $165 from $155 at Wells Fargo
11/05/20 Roth Capital
Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30
11/02/20 Deutsche Bank
Massachusetts order could impact Wynn, Penn and MGM, says Deutsche Bank
11/02/20 Morgan Stanley
Wynn Resorts upgraded to Overweight at Morgan Stanley after 48% year-to-date dip
CZR Caesars
$70.04 /

+0.73 (+1.05%)

11/25/20
Fly Intel: Top five analyst downgrades
11/25/20 Morgan Stanley
Caesars cut to Equal Weight on near-term lockdown risks at Morgan Stanley
11/25/20 Morgan Stanley
Caesars downgraded to Equal Weight from Overweight at Morgan Stanley
11/02/20 Jefferies
Jefferies upgrades Gaming and Leisure on deal opportunities, tenant health
CHDN Churchill Downs
$185.21 /

+0.4 (+0.22%)

09/25/20
Fly Intel: Top five analyst upgrades
09/25/20 Jefferies
Jefferies thinks better entry points may be coming for Churchill Downs shares
09/25/20 Susquehanna
Susquehanna upgrades Churchill Downs to Positive on court ruling selloff
09/10/20
Fly Intel: Top five analyst downgrades
PENN Penn National
$73.31 /

+0.91 (+1.26%)

11/19/20 Piper Sandler
Penn National initiated with an Overweight at Piper Sandler
11/17/20 Loop Capital
Penn National initiated with a Hold at Loop Capital
11/16/20 Loop Capital
Penn National initiated with a Hold at Loop Capital
11/16/20 Craig-Hallum
October NJ sports betting wagers set 3rd consecutive record, says Craig-Hallum
WYNN Wynn Resorts
$101.26 /

+0.86 (+0.86%)

11/19/20 Morgan Stanley
Wynn Resorts price target raised to $120 from $100 at Morgan Stanley
11/17/20 JPMorgan
Wynn Resorts price target raised to $106 from $96 at JPMorgan
11/09/20 Credit Suisse
Wynn Resorts price target raised to $80 from $72 at Credit Suisse
11/06/20 Deutsche Bank
Wynn Resorts price target raised to $95 from $93 at Deutsche Bank
LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

11/17/20
Fly Intel: Top five analyst downgrades
11/17/20 JPMorgan
Las Vegas Sands price target raised to $62 from $58 at JPMorgan
11/17/20 HSBC
Las Vegas Sands downgraded to Hold on Macau recovery pace at HSBC
11/16/20 HSBC
Las Vegas Sands downgraded to Hold from Buy at HSBC
GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

11/17/20 B. Riley Securities
Gan Limited price target lowered to $27 from $28.50 at B. Riley Securities
10/15/20 Craig-Hallum
Strong results in NJ to encourage states to legalize iGaming, says Craig-Hallum
10/06/20 B. Riley Securities
Gan Limited shares have more room to run, says B. Riley Securities
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

05:51 Today Jefferies
Jefferies views Canada sports betting steps as positive for Flutter
11/20/20 Redburn
Flutter Entertainment downgraded to Neutral from Buy at Redburn
11/17/20 Morgan Stanley
Flutter price target raised to 13,000 GBp from 11,500 GBp at Morgan Stanley
11/12/20 Deutsche Bank
Flutter price target raised to 12,387 GBp from 11,800 GBp at Deutsche Bank
WIMHY William Hill
$0.00 /

+ (+0.00%)

11/13/20 HSBC
William Hill downgraded to Hold from Buy at HSBC
10/27/20 RBC Capital
William Hill price target lowered to 272 GBp from 300 GBp at RBC Capital
10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
10/02/20
Fly Intel: Top five analyst downgrades
DKNG DraftKings
$52.59 /

+2.35 (+4.68%)

11/24/20
Fly Intel: Top five analyst initiations
11/24/20 UBS
DraftKings initiated with a Neutral at UBS
11/19/20 Piper Sandler
DraftKings initiated with an Overweight at Piper Sandler
11/17/20
Fly Intel: Top five analyst initiations
WYNN Wynn Resorts
$101.26 /

+0.86 (+0.86%)

PENN Penn National
$73.31 /

+0.91 (+1.26%)

MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DKNG DraftKings
$52.59 /

+2.35 (+4.68%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

CHDN Churchill Downs
$185.21 /

+0.4 (+0.22%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

  • 07
    Oct
  • 29
    Sep
  • 25
    Sep
  • 19
    Jun
  • 12
    May
  • 05
    May
PENN Penn National
$73.31 /

+0.91 (+1.26%)

MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

WYNN Wynn Resorts
$101.26 /

+0.86 (+0.86%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

PENN Penn National
$73.31 /

+0.91 (+1.26%)

MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

CHDN Churchill Downs
$185.21 /

+0.4 (+0.22%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

WYNN Wynn Resorts
$101.26 /

+0.86 (+0.86%)

PENN Penn National
$73.31 /

+0.91 (+1.26%)

MGM MGM Resorts
$28.64 /

+0.24 (+0.85%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DKNG DraftKings
$52.59 /

+2.35 (+4.68%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 15:22
11/27/20
11/27
15:22
11/27/20
15:22
DRRX

Durect

$1.82 /

-0.045 (-2.41%)

Pharmaceuticals &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

11/23/20 Chardan
Durect positioned for 'market dominance' in alcoholic hepatitis, says Chardan
11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

DRRX Durect
$1.82 /

-0.045 (-2.41%)

Technical Analysis
NASDAQ market internals summary » 15:17
11/27/20
11/27
15:17
11/27/20
15:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Volume is above average for this time of day. Breadth is bullish across the board. Advancing Issues: 2249 / Declining Issues: 1300 -- for a ratio of 1.7 to 1. Advancing Volume: 2,656,883,000 / Declining Volume: 678,991,000 -- for a ratio of 3.9 to 1. New 52-Week Highs: 302 / New 52-Week Lows: 14.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 15:16
11/27/20
11/27
15:16
11/27/20
15:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Conference/Events
Trilogy Metals management to meet virtually with Cantor Fitzgerald » 15:14
11/27/20
11/27
15:14
11/27/20
15:14
TMQ

Trilogy Metals

$1.74 /

+0.05 (+2.96%)

Virtual Meeting to be…

Virtual Meeting to be held on December 4 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
TMQ Trilogy Metals
$1.74 /

+0.05 (+2.96%)

TMQ Trilogy Metals
$1.74 /

+0.05 (+2.96%)

11/03/20 TD Securities
Trilogy Metals price target lowered to C$3 from C$3.50 at TD Securities
07/24/20 TD Securities
Trilogy Metals downgraded to Hold from Speculative Buy at TD Securities
07/10/20 TD Securities
Trilogy Metals price target raised to C$3.50 from C$3 at TD Securities
05/13/20 BMO Capital
Trilogy Metals initiated with an Outperform at BMO Capital
Conference/Events
Harborside participates in a conference call with Cantor Fitzgerald » 15:12
11/27/20
11/27
15:12
11/27/20
15:12
HSDEF

Harborside

$0.00 /

+ (+0.00%)

rConference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HSDEF Harborside
$0.00 /

+ (+0.00%)

HSDEF Harborside
$0.00 /

+ (+0.00%)

HSDEF Harborside
$0.00 /

+ (+0.00%)

Conference/Events
Kindred Biosciences participates in a conference call with Cantor Fitzgerald » 15:04
11/27/20
11/27
15:04
11/27/20
15:04
KIN

Kindred Biosciences

$3.91 /

-0.09 (-2.25%)

Conference call with…

Conference call with management will be held on November 30 at 2 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

07/29/20 Cantor Fitzgerald
Kindred Biosciences price target lowered to $11 from $25 at Cantor Fitzgerald
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
KIN Kindred Biosciences
$3.91 /

-0.09 (-2.25%)

Conference/Events
Morgan Stanley sustainability analysts hold analyst/industry conference call » 14:46
11/27/20
11/27
14:46
11/27/20
14:46

Global Head of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Technical Analysis
NASDAQ market internals summary » 14:17
11/27/20
11/27
14:17
11/27/20
14:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Volume is above average for this time of day. Breadth is bullish across the board. Advancing Issues: 2249 / Declining Issues: 1300 -- for a ratio of 1.7 to 1. Advancing Volume: 2,632,632,000 / Declining Volume: 676,439,000 -- for a ratio of 3.9 to 1. New 52-Week Highs: 302 / New 52-Week Lows: 14.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 14:16
11/27/20
11/27
14:16
11/27/20
14:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Conference/Events
Morgan Stanley municipal strategists hold analyst/industry conference call » 14:15
11/27/20
11/27
14:15
11/27/20
14:15

Chief Municipal…

Chief Municipal Strategist Zezas, Municipal Strategist Boakye and Co-head of Municipal Desk Credit Analytics Schmidt discuss the 2021 Municipal Outlook on an Analyst/Industry conference call to be held on December 2 at 11 am.

Conference/Events
Morgan Stanley cable/telecom analysts hold analyst/industry conference call » 14:03
11/27/20
11/27
14:03
11/27/20
14:03

US Equity Telecom…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Treasury Market Summary » 13:50
11/27/20
11/27
13:50
11/27/20
13:50

Treasury Market Summary:…

Treasury Market Summary: it was a short, sweet, and thinly traded session in the markets following the Thanksgiving holiday. Both stocks and bonds closed their abbreviated sessions with gains, with more new highs on Wall Street. The NASDAQ led the rally, climbing 0.9% to 12,205, yet another new peak. Similarly, the S&amp;P 500 finished 0.25% firmer at its fresh all-time high just over 3638. The Dow was up 0.13%, at 29,910 after hitting 30,046 on Tuesday. Treasuries captured a solid bid, front running a big month-end extension which saw the long end outperform. Despite some of the renewed enthusiasm toward equities that's seen more record highs this week, the virus and the shutdowns are supporting demand for the safety of bonds. There was also some concern over potential tensions with Iran after it threatened retaliation after a top nuclear scientist was kill. The calendar was empty, leaving the markets to their own devices. View the summary.

Conference/Events
Morgan Stanley European economists to hold analyst/industry conference call » 13:45
11/27/20
11/27
13:45
11/27/20
13:45

Chief Cross-Asset…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
SIFMA Rec. Early Close 2:00 ET to be released at 14:00  13:45
11/27/20
11/27
13:45
11/27/20
13:45
 
General news
SIFMA Rec. Early Close 2:00 ET to be released at 14:00  13:45
11/27/20
11/27
13:45
11/27/20
13:45
 
On The Fly
Bet On It: Canada sets sights on decriminalizing single event sport betting » 13:39
11/27/20
11/27
13:39
11/27/20
13:39
BYD

Boyd Gaming

$39.57 /

+0.18 (+0.46%)

, CZR

Caesars

$70.04 /

+0.73 (+1.05%)

, LVS

Las Vegas Sands

$56.61 /

+0.09 (+0.16%)

, MGM

MGM Resorts

$28.57 /

+0.17 (+0.60%)

, PENN

Penn National

$73.40 /

+1 (+1.38%)

, WYNN

Wynn Resorts

$101.17 /

+0.77 (+0.77%)

, DMYT

dMY Technology Group

$16.16 /

-0.01 (-0.06%)

, PDYPY

Flutter Entertainment

$0.00 /

+ (+0.00%)

, DKNG

DraftKings

$52.53 /

+2.29 (+4.56%)

, BALY

Bally's

$46.70 /

-0.765 (-1.61%)

, WIMHY

William Hill

$0.00 /

+ (+0.00%)

, GAN

Gan Limited

$16.47 /

+0.3 (+1.86%)

Welcome to The Fly's…

ShowHide Related Items >><<
WIMHY William Hill
$0.00 /

+ (+0.00%)

PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

MGM MGM Resorts
$28.57 /

+0.17 (+0.60%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DMYT dMY Technology Group
$16.16 /

-0.01 (-0.06%)

DKNG DraftKings
$52.53 /

+2.29 (+4.56%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

BALY Bally's
$46.70 /

-0.765 (-1.61%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

10/30/20 Argus
Boyd Gaming upgraded to Buy from Hold at Argus
10/30/20 Argus
Boyd Gaming upgraded to Buy from Hold at Argus
10/28/20 Union Gaming
Union Gaming says 'better late than never,' upgrades Red Rock Resorts to Buy
10/27/20 Stifel
Boyd Gaming price target raised to $48 from $28 at Stifel
CZR Caesars
$70.04 /

+0.73 (+1.05%)

11/25/20
Fly Intel: Top five analyst downgrades
11/25/20 Morgan Stanley
Caesars cut to Equal Weight on near-term lockdown risks at Morgan Stanley
11/25/20 Morgan Stanley
Caesars downgraded to Equal Weight from Overweight at Morgan Stanley
11/02/20 Jefferies
Jefferies upgrades Gaming and Leisure on deal opportunities, tenant health
LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

11/17/20
Fly Intel: Top five analyst downgrades
11/17/20 JPMorgan
Las Vegas Sands price target raised to $62 from $58 at JPMorgan
11/17/20 HSBC
Las Vegas Sands downgraded to Hold on Macau recovery pace at HSBC
11/16/20 HSBC
Las Vegas Sands downgraded to Hold from Buy at HSBC
MGM MGM Resorts
$28.57 /

+0.17 (+0.60%)

11/10/20 Wells Fargo
IAC price target raised to $165 from $155 at Wells Fargo
11/05/20 Roth Capital
Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30
11/02/20 Deutsche Bank
Massachusetts order could impact Wynn, Penn and MGM, says Deutsche Bank
11/02/20 Morgan Stanley
Wynn Resorts upgraded to Overweight at Morgan Stanley after 48% year-to-date dip
PENN Penn National
$73.40 /

+1 (+1.38%)

11/19/20 Piper Sandler
Penn National initiated with an Overweight at Piper Sandler
11/17/20 Loop Capital
Penn National initiated with a Hold at Loop Capital
11/16/20 Loop Capital
Penn National initiated with a Hold at Loop Capital
11/16/20 Craig-Hallum
October NJ sports betting wagers set 3rd consecutive record, says Craig-Hallum
WYNN Wynn Resorts
$101.17 /

+0.77 (+0.77%)

11/19/20 Morgan Stanley
Wynn Resorts price target raised to $120 from $100 at Morgan Stanley
11/17/20 JPMorgan
Wynn Resorts price target raised to $106 from $96 at JPMorgan
11/09/20 Credit Suisse
Wynn Resorts price target raised to $80 from $72 at Credit Suisse
11/06/20 Deutsche Bank
Wynn Resorts price target raised to $95 from $93 at Deutsche Bank
DMYT dMY Technology Group
$16.16 /

-0.01 (-0.06%)

11/25/20 Benchmark
dMY Technology Group price target raised to $21 after earnings at Benchmark
09/23/20 Benchmark
dMY Technology Group initiated with a Buy at Benchmark
PDYPY Flutter Entertainment
$0.00 /

+ (+0.00%)

05:51 Today Jefferies
Jefferies views Canada sports betting steps as positive for Flutter
11/20/20 Redburn
Flutter Entertainment downgraded to Neutral from Buy at Redburn
11/17/20 Morgan Stanley
Flutter price target raised to 13,000 GBp from 11,500 GBp at Morgan Stanley
11/12/20 Deutsche Bank
Flutter price target raised to 12,387 GBp from 11,800 GBp at Deutsche Bank
DKNG DraftKings
$52.53 /

+2.29 (+4.56%)

11/24/20
Fly Intel: Top five analyst initiations
11/24/20 UBS
DraftKings initiated with a Neutral at UBS
11/19/20 Piper Sandler
DraftKings initiated with an Overweight at Piper Sandler
11/17/20
Fly Intel: Top five analyst initiations
BALY Bally's
$46.70 /

-0.765 (-1.61%)

11/20/20 Truist
Bally's price target raised to $65 from $32 at Truist
11/20/20 Benchmark
Sinclair Broadcast price target raised to $35 from $28 at Benchmark
WIMHY William Hill
$0.00 /

+ (+0.00%)

11/13/20 HSBC
William Hill downgraded to Hold from Buy at HSBC
10/27/20 RBC Capital
William Hill price target lowered to 272 GBp from 300 GBp at RBC Capital
10/05/20 JPMorgan
Caesars price target raised to $67 from $63 at JPMorgan
10/02/20
Fly Intel: Top five analyst downgrades
GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

11/17/20 B. Riley Securities
Gan Limited price target lowered to $27 from $28.50 at B. Riley Securities
10/15/20 Craig-Hallum
Strong results in NJ to encourage states to legalize iGaming, says Craig-Hallum
10/06/20 B. Riley Securities
Gan Limited shares have more room to run, says B. Riley Securities
WYNN Wynn Resorts
$101.17 /

+0.77 (+0.77%)

PENN Penn National
$73.40 /

+1 (+1.38%)

MGM MGM Resorts
$28.57 /

+0.17 (+0.60%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DMYT dMY Technology Group
$16.16 /

-0.01 (-0.06%)

DKNG DraftKings
$52.53 /

+2.29 (+4.56%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

BALY Bally's
$46.70 /

-0.765 (-1.61%)

  • 07
    Oct
  • 29
    Sep
  • 25
    Sep
  • 19
    Jun
  • 12
    May
  • 05
    May
PENN Penn National
$73.40 /

+1 (+1.38%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

WYNN Wynn Resorts
$101.17 /

+0.77 (+0.77%)

WIMHY William Hill
$0.00 /

+ (+0.00%)

PENN Penn National
$73.40 /

+1 (+1.38%)

MGM MGM Resorts
$28.57 /

+0.17 (+0.60%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DMYT dMY Technology Group
$16.16 /

-0.01 (-0.06%)

DKNG DraftKings
$52.53 /

+2.29 (+4.56%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

WYNN Wynn Resorts
$101.17 /

+0.77 (+0.77%)

PENN Penn National
$73.40 /

+1 (+1.38%)

MGM MGM Resorts
$28.57 /

+0.17 (+0.60%)

LVS Las Vegas Sands
$56.61 /

+0.09 (+0.16%)

GAN Gan Limited
$16.47 /

+0.3 (+1.86%)

DMYT dMY Technology Group
$16.16 /

-0.01 (-0.06%)

DKNG DraftKings
$52.53 /

+2.29 (+4.56%)

CZR Caesars
$70.04 /

+0.73 (+1.05%)

BYD Boyd Gaming
$39.57 /

+0.18 (+0.46%)

General news
Fedspeak will be of interest in the week ahead with Chair Powell headlining » 13:20
11/27/20
11/27
13:20
11/27/20
13:20

Fedspeak will be of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

On The Fly
Fly Intel: Wall Street's top stories for Friday » 13:17
11/27/20
11/27
13:17
11/27/20
13:17
AZN

AstraZeneca

$52.59 /

-0.01 (-0.02%)

, MRNA

Moderna

$126.88 /

+17.7 (+16.21%)

, NVAX

Novavax

$125.68 /

+23.16 (+22.59%)

, SAGE

Sage Therapeutics

$75.59 /

-7.02 (-8.50%)

, BIIB

Biogen

$243.90 /

+1.85 (+0.76%)

, RYTM

Rhythm Pharmaceuticals

$29.27 /

+5.16 (+21.40%)

, MARA

Marathon Patent Group

$4.29 /

-0.805 (-15.80%)

, RIOT

Riot Blockchain

$6.25 /

-0.825 (-11.66%)

Stock futures saw modest…

ShowHide Related Items >><<
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

07:39 Today Argus
AstraZeneca's COVID vaccine faces high bar for FDA authorization, says Argus
06:25 Today Citi
Citi opens 'positive catalyst watch' on AstraZeneca after vaccine selloff
11/24/20 Piper Sandler
Astra vaccine results 'de-risking' for Altimmune, says Piper Sandler
11/23/20 Morgan Stanley
AstraZeneca price target raised to 9,400 GBp from 9,000 GBp at Morgan Stanley
MRNA Moderna
$126.88 /

+17.7 (+16.21%)

11/25/20 Goldman Sachs
Moderna price target raised to $139 from $107 at Goldman Sachs
11/23/20
Fly Intel: Top five analyst initiations
11/23/20 Wells Fargo
Moderna initiated with an Equal Weight at Wells Fargo
NVAX Novavax
$125.68 /

+23.16 (+22.59%)

11/17/20 H.C. Wainwright
Novavax price target lowered to $207 from $290 at H.C. Wainwright
10/30/20 Cantor Fitzgerald
Cantor says Novavax vaccine could be 'best-in-class,' but not 'first-in-class'
10/22/20 B. Riley Securities
Novavax price target lowered to $223 from $257 at B. Riley Securities
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

10:16 Today Stifel
Stifel says license deal 'good' for Biogen, takes some upside off table for Sage
11/19/20 Oppenheimer
Sage Therapeutics price target raised to $94 from $65 at Oppenheimer
11/16/20
Fly Intel: Top five analyst downgrades
11/16/20 Morgan Stanley
Morgan Stanley downgrades Sage Therapeutics amid 'reasonable' expectations
BIIB Biogen
$243.90 /

+1.85 (+0.76%)

11/10/20 Truist
Truist raises Biogen price target to $443, views aducanumab approval as 'likely'
11/10/20 DZ Bank
Biogen upgraded to Buy from Hold at DZ Bank
11/09/20 BMO Capital
Biogen price target lowered to $253 from $343 at BMO Capital
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

11:25 Today Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
10/26/20 Stifel
Rhythm Pharmaceuticals price target raised to $36 from $31 at Stifel
01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

11/23/20 H.C. Wainwright
Marathon Patent Group initiated with a Buy at H.C. Wainwright
RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

11/23/20 H.C. Wainwright
Riot Blockchain price target raised to $7.50 from $3.50 at H.C. Wainwright
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

  • 24
    Jul
  • 19
    May
  • 12
    Feb
NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.